(责任编辑：关婧) 嘉和美康首次公开发行股票募集资金总额13.62亿元，扣除发行费用后，募集资金净额为12.40亿 元。嘉和美康最终募集资金净额比原计划多4.90亿元。嘉和美康于2021年12月9日披露的招股说明书显 示，该公司拟募集资金7.50亿元，分别用于专科电子病历研发项目（急诊急救方向、妇幼专科方向）、 综合电子病历升级改造项目、数据中心升级改造项目、补充营运资金。 嘉和美康首次公开发行股票的发行费用总额为1.21亿元，其中，保荐及承销费用9782.30万元。 中国经济网北京1月16日讯 嘉和美康(688246.SH)今日股价下跌，截至收盘报29.00元，跌幅7.20%。 目前该股处于破发状态。 嘉和美康于2021年12月14日在上交所科创板上市，发行价格为39.50元/股，发行数量为3446.94万 股，保荐机构（主承销商）为华泰联合证券有限责任公司，保荐代表人为孔祥熙、王琛。 ...

Group 1 - The AI healthcare and AI pharmaceutical sectors experienced significant fluctuations, with notable declines in stock prices [1] - Hongbo Pharmaceutical saw a drop of over 18%, while Nossger fell nearly 15% [1] - Other companies such as International Medicine, Boji Pharmaceutical, Jiahe Meikang, and Berry Genomics also reported declines exceeding 5% [1]

Investment Rating - The report rates the AI healthcare industry as "Overweight," indicating a positive outlook for the sector compared to the overall market performance [2][19]. Core Insights - The launch of OpenAI's ChatGPT Health on January 8, 2026, marks a significant advancement in AI healthcare, integrating user health data for personalized health analysis and recommendations. The user base of Ant Group's AI tool, Antifufu, has also seen substantial growth, surpassing 30 million monthly active users [2][5]. - The report highlights the rapid penetration of AI health management in the consumer market, driven by advancements in technology and user engagement [2][5]. - Key areas of progress include AI consultations, brain-computer interfaces, and AI-driven drug development, with notable advancements from companies like Neuralink and Retro Biosciences [10][13][14]. Summary by Sections AI Health Management - OpenAI's ChatGPT Health integrates personal health data, offering features such as test report interpretation, health management, and personalized diet and fitness recommendations. The tool emphasizes user privacy and data security [4][7]. - Antifufu has integrated over 100 AI functions, connecting users with 300,000 real doctors and over 500 AI avatars, achieving a doubling in user engagement metrics within a month [8][9]. AI Consultation and Drug Development - The report notes significant improvements in AI consultation tools, with various companies like Weining Health and JD Health being highlighted for their contributions to AI health management [15]. - In drug development, OpenAI's collaboration with Retro Biosciences has led to the clinical advancement of a small molecule drug targeting aging, showcasing the potential of AI in pharmaceutical innovation [13][14]. Market Performance and Company Valuations - The report provides a valuation table for key companies in the AI healthcare sector, indicating projected net profits and market capitalizations for 2024 to 2027. For instance, Weining Health is projected to have a market cap of 31 billion with a net profit of 3.5 billion by 2026 [14].

Group 1 - The AI medical concept is experiencing significant activity, with companies like Dean Diagnostics and Hongbo Pharmaceutical hitting the 20% daily limit increase [1] - Meian Health has achieved a three-day consecutive increase, indicating strong market interest [1] - Other companies such as Jiahe Meikang and Chengdu Xian Dao have seen increases of over 10%, while Anbiping, Weining Health, Yaoshi Technology, and Guoxin Health are also following the upward trend [1]

证券代码：688246 证券简称：嘉和美康 公告编号：2026-001 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 大股东持有的基本情况 本次减持计划实施前，嘉和美康（北京）科技股份有限公司（以下简"嘉和美康"或"公司"）股东弘云久 康数据技术（北京）有限公司（以下简称"弘云久康"）持有公司股份 8,485,931股，占公司股份总数的 6.17%。上述股份为嘉和美康首次公开发行并上市前取得的股份，且已于2022年12月14日起上市流通。 ● 减持计划的实施结果情况 公司于2025年9月5日披露了《嘉和美康持股5%以上股东减持股份计划公告》（公告编号：2025- 061），弘云久康因自身流动性需求，计划自2025年10月9日起3个月内根据市场情况通过集中竞价方式 减持其持有的公司股份合计不超过1,375,855股，即不超过公司总股本的1%。 公司于近日收到弘云久康出具的《关于股份减持结果的告知函》，其在2025年10月9日至2026年1月8日 期间未减持公司股份，本次股份减持计划时间区间届满 ...

证券日报网讯 1月9日，嘉和美康发布公告称，本次减持计划实施前，公司股东弘云久康数据技术（北 京）有限公司（简称"弘云久康"）持有公司股份8，485，931股，占公司股份总数的6.17%。公司于2025 年9月5日披露了《嘉和美康持股5%以上股东减持股份计划公告》（公告编号：2025-061），弘云久康 因自身流动性需求，计划自2025年10月9日起3个月内根据市场情况通过集中竞价方式减持其持有的公司 股份合计不超过1，375，855股，即不超过公司总股本的1%。公司于近日收到弘云久康出具的《关于股 份减持结果的告知函》，其在2025年10月9日至2026年1月8日期间未减持公司股份，本次股份减持计划 时间区间届满。 （文章来源：证券日报） ...

Core Viewpoint - Jiahe Meikang (688246.SH) has received a notification from Hongyun Jiukang regarding the results of its share reduction plan, indicating that no shares were reduced during the specified period from October 9, 2025, to January 8, 2026 [1] Group 1 - The share reduction plan's time frame has now expired without any shares being sold [1]

证券代码：688246 证券简称：嘉和美康 公告编号：2026-001 嘉和美康（北京）科技股份有限公司 持股 5%以上股东减持计划时间届满 暨未减持股份的结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 本次减持计划实施前，嘉和美康（北京）科技股份有限公司（以下简"嘉和 美康"或"公司"）股东弘云久康数据技术（北京）有限公司（以下简称"弘云 久康"）持有公司股份 8,485,931 股，占公司股份总数的 6.17%。上述股份为嘉 和美康首次公开发行并上市前取得的股份，且已于 2022 年 12 月 14 日起上市流 通。 减持计划的实施结果情况 公司于 2025 年 9 月 5 日披露了《嘉和美康持股 5%以上股东减持股份计划公 告》（公告编号：2025-061），弘云久康因自身流动性需求，计划自 2025 年 10 月9日起3个月内根据市场情况通过集中竞价方式减持其持有的公司股份合计不 超过 1,375,855 股，即不超过公司总股本的 1%。 公司于近日收到弘 ...

嘉和美康公告称，股东弘云久康在减持计划实施前持有公司8485931股，占比6.17%。2025年9月5日， 公司披露弘云久康减持计划，拟自2025年10月9日起3个月内，通过集中竞价减持不超1375855股，即不 超总股本1%。2025年10月9日至2026年1月8日，弘云久康未减持公司股份，减持计划时间区间届满，目 前仍持股8485931股，占比6.17%。 ...

Core Viewpoint - The DRG/DIP concept has seen a significant increase of 5.67%, ranking third among concept sectors, with 21 stocks rising, including a 20% surge in Di'an Diagnostics, and several other stocks reaching their daily limit up [1][2]. Group 1: Market Performance - The DRG/DIP concept sector experienced a net inflow of 350 million yuan, with 14 stocks receiving net inflows, and 7 stocks attracting over 30 million yuan each [2]. - Di'an Diagnostics led the net inflow with 290 million yuan, followed by Jiuyuan Yinhai and Guoxin Health with net inflows of 206 million yuan and 127 million yuan, respectively [2][3]. Group 2: Stock Performance - The top performers in the DRG/DIP concept included: - Di'an Diagnostics with a 20% increase and a turnover rate of 20.80% [3]. - Jiuyuan Yinhai with a 10.02% increase and a turnover rate of 10.61% [3]. - Guoxin Health with a 10.01% increase and a turnover rate of 2.90% [3]. - Other notable stocks include: - Weining Health with a 13.79% increase and a turnover rate of 18.16% [4]. - Jiahe Meikang with an 11.17% increase and a turnover rate of 13.98% [3].